Insider Trading March 31, 2026

Globe Life Executive Sells $1.2M in Shares Following Option Exercise

EVP and Chief Talent Officer Rebecca E. Zorn completed multiple share sales the same day she exercised options to buy 8,800 shares

By Priya Menon GL
Globe Life Executive Sells $1.2M in Shares Following Option Exercise
GL

Rebecca E. Zorn, Globe Life Inc.'s EVP and Chief Talent Officer, sold $1,202,189 of company stock on March 31, 2026 in three transactions after exercising options to acquire 8,800 shares at $98.32. The filings detail sale prices between $135.6593 and $137.4038. The disclosures come amid a recent quarterly earnings miss, a dividend increase, board expansion and a new analyst coverage initiation.

Key Points

  • Rebecca E. Zorn, Globe Life EVP and Chief Talent Officer, sold $1,202,189 in company stock on March 31, 2026 in three transactions priced between $135.6593 and $137.4038 per share.
  • On March 31, 2026, Zorn exercised options to acquire 8,800 Globe Life shares at an exercise price of $98.32, with total exercise value of $865,215.
  • Recent company developments include a Q4 2025 EPS miss ($3.39 vs $3.44 expected), revenue of $1.52 billion versus $1.53 billion forecast, a raised quarterly dividend to $0.33 per share, board expansion to 14 members, and a new buy rating from Texas Capital Securities with a $170 price target.

Rebecca E. Zorn, executive vice president and chief talent officer at Globe Life Inc. (NYSE: GL), reported the sale of company stock totaling $1,202,189 on March 31, 2026, according to a Form 4 filed with the Securities and Exchange Commission.

The filing shows the shares were sold in three separate transactions. The amounts disposed were 2,126 shares, 4,724 shares and 1,950 shares. Transaction prices ranged from $135.6593 to $137.4038 per share.


On the same date as the sales, Zorn exercised options to acquire 8,800 shares of Globe Life common stock at an exercise price of $98.32 per share, for a total exercise value of $865,215.

These movements were recorded in the standard SEC disclosure that informs shareholders and market participants of insider trading and option activity.


Separately, third-party analysis noted in the disclosure indicates that Globe Life appears undervalued at current market levels, according to InvestingPro. The same analysis highlights that the company has raised its dividend for 10 consecutive years. Investors can access a broader Pro Research Report covering more than 1,400 U.S. equities for additional context, per the filing.


The insider transactions arrive in a period of several recent corporate developments for Globe Life. In its fourth-quarter 2025 results, the company posted earnings per share of $3.39, short of the expected $3.44. Revenue for the quarter was reported at $1.52 billion, slightly below the forecast of $1.53 billion.

Globe Life also announced an increase to its quarterly dividend to $0.33 per share, payable on May 1, 2026, to shareholders of record as of April 3, 2026.


In governance moves disclosed by the company, the board of directors expanded from twelve to fourteen members. Derek T. Kan and Sandra L. Phillips were appointed to the new seats; their terms run until the company’s annual meeting of shareholders scheduled for April 30, 2026.

Market coverage activity noted in the disclosure includes Texas Capital Securities initiating coverage on Globe Life with a buy rating and a price target of $170, which the report states implies a 23% total return.


The Form 4 filing for Zorn’s transactions and the accompanying corporate disclosures provide a snapshot of insider activity and recent company developments without offering forward guidance. The sales, option exercise and corporate updates are recorded events disclosed to the market and documented through the SEC filing process.

Risks

  • Earnings and revenue shortfalls - The company reported Q4 2025 EPS and revenue slightly below expectations, which may affect investor sentiment in the insurance and financials sectors.
  • Insider transaction timing - Significant insider sales following an option exercise can raise questions among shareholders regarding timing and liquidity decisions, affecting perception in the equities market.
  • Governance transition uncertainty - Recent board expansion and new appointments introduce near-term changes to oversight that may affect strategic direction until the annual meeting, with implications for corporate governance in the insurance sector.

More from Insider Trading

Platinum Equity Disposes of 1.35M Ingram Micro Shares in $28.8M Trade Mar 31, 2026 Adaptive Biotechnologies President Disposes of $751k in Stock While Exercising Options Mar 31, 2026 Palladyne AI CFO Sells Small Block of Stock to Cover RSU Taxes; Company Posts Strong Revenue Gain but Remains Unprofitable Mar 31, 2026 Palladyne AI Chief Legal Officer Sells $19,251 in Stock to Cover RSU Taxes Mar 31, 2026 Palladyne AI CTO Sells $84,020 in Stock to Cover RSU Taxes Mar 31, 2026